Industry / Pharma and Life Sciences
Pharma contracts carry regulatory obligations that do not appear on the face of the agreement.
Zeal reads the legal vocabulary of clinical development, IP licensing, and manufacturing compliance and converts it into structured intelligence your organization can act on.
The contract is where regulatory exposure lives.
A clinical trial agreement allocates pharmacovigilance responsibilities between sponsor and site. An IP licensing agreement defines milestone triggers tied to regulatory submissions. A contract manufacturing agreement contains quality and deviation-reporting obligations that parallel FDA and EMA requirements. None of these obligations are managed well by a system that stores documents without understanding them.
Pharma legal and regulatory teams operate across portfolios of agreements whose obligations intersect in ways that are difficult to track manually. A missed milestone notification in a co-development agreement can trigger a renegotiation that delays a program. An unmonitored deviation-reporting clause in a CMO contract can produce a compliance gap that surfaces in an inspection. The cost of those misses is not measured in legal fees. It is measured in program timelines.
Zeal applies AI legal intelligence to the specific language structures that govern pharma relationships: clinical, IP, manufacturing, and regulatory compliance contracts, each understood on its own terms and monitored as a live obligation.
What Zeal reads in pharma contracts
Four contract categories, each with distinct legal vocabulary and distinct intelligence requirements.
Clinical Trial Agreements
CTAs define the allocation of pharmacovigilance obligations, data ownership, IP rights arising from the trial, publication rights, and indemnification between sponsor, CRO, and site. Zeal extracts and monitors each of these dimensions across a trial portfolio, surfacing the agreements where obligations are approaching, where language deviates from standard sponsor terms, and where counterparty obligations have not been fulfilled on schedule.
IP Licensing and Co-Development Agreements
Royalty tiers, milestone payment triggers, field-of-use restrictions, sublicensing rights, and reversion clauses define the economic and strategic value of a pharma IP portfolio. Zeal maps each agreement's milestone structure to a tracked calendar and monitors field-of-use and territory restrictions to surface conflicts before they become disputes. When regulatory submission milestones approach, the platform flags the relevant agreements and the obligations they trigger.
Contract Manufacturing Agreements
CMO agreements embed GMP compliance obligations, deviation and CAPA reporting requirements, batch record retention terms, and audit rights that must remain live across the life of the agreement. Zeal monitors these obligations continuously, identifies when audit windows are opening, and flags deviation-reporting clauses that require active counterparty compliance. The platform distinguishes between obligations that are self-executing and those that require a triggering event from the CMO.
Regulatory Compliance Contracts
Distribution agreements, pharmacovigilance agreements, and consent forms each carry jurisdiction-specific regulatory obligations that change as regulatory frameworks evolve. Zeal tracks the regulatory reference points embedded in these agreements and alerts when external regulatory changes intersect with existing contractual language. A change to FDA adverse event reporting timelines, for example, can create compliance exposure in existing PVAs that reference the prior standard.
What the intelligence produces
Zeal converts pharma contract language into three categories of operational intelligence.
Regulatory obligation tracking
Zeal identifies every obligation with a regulatory dimension across the portfolio: reporting deadlines, audit triggers, GMP compliance milestones, and jurisdiction-specific requirements. Each obligation is tracked against a live calendar and surfaced to the responsible team before the deadline, not after.
IP portfolio management
The platform maps the economic and legal structure of every IP agreement: royalty tiers, milestone triggers, field-of-use restrictions, exclusivity windows, and reversion rights. When a regulatory submission milestone approaches, Zeal identifies which agreements it activates and what the downstream obligations are.
Compliance monitoring across CMO relationships
Contract manufacturing agreements require ongoing counterparty compliance. Zeal tracks deviation-reporting obligations, audit rights, and CAPA response timelines across the full CMO portfolio, distinguishing between obligations that run continuously and those triggered by specific manufacturing events.
See how Zeal maps your pharma contract portfolio.
Request a briefing to walk through how Zeal applies to your specific contract types, regulatory obligations, and IP portfolio.